References:
- Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney
disease. The. Lancet. 2007:1287-1301. 10.1016/S0140-6736(07)60601-1
- Hessheimer AJ, Vidal O, Valentini M, García-Valdecasas
JC: Pheochromocytoma as a rare cause of arterial hypertension in a
patient with autosomal dominant polycystic kidney disease: A
diagnostic and therapeutic dilemma. International Journal of Surgery
Case Reports. 2015:85-88. 10.1016/j.ijscr.2015.07.015
- Sedaia E, Esanu A, Ivanov V, et al.: Catecholamine-induced
cardiomyopathy in a patient with pheochromocytoma and polycystic
kidney and liver disease: a case report. European Heart Journal - Case
Reports. 2019:062. 10.1093/ehjcr/ytz062
- Mansi L, Rambaldi PF, Marino G, Argenziano G, Sandomenico F, Vecchio
ED. Pheochromocytoma Diagnosed With 1-123 MIBG Scintigraphy in a
Patient With Concomitant Bilateral Polycystic Kidneys: CLINICAL
NUCLEAR MEDICINE (1997: 22:268-270. 10.1097/00003072-199704000-00019
- Quiñonero Díaz A, García Hirschfeld J, Alonso Dorrego JM, Marchal
Escalona C, Machuca Santa Cruz J, Marín Martín JA: Rotura esponánea de
feocromocitoma en paciente con riñones poliquísticos: A propósito de
un caso [Spontaneous rupture of pheochromocytoma in a patient with
polycystic kidneys. Apropos of a case]. Archivos espanoles de
urologia. 50:1117-9.
- Mete O, Asa SL, Gill AJ, Kimura N, De Krijger RR, Tischler A: Overview
of the 2022 WHO Classification of Paragangliomas and
Pheochromocytomas. Endocr Pathol.
2022:90-114. 10.1007/s12022-022-09704-6
- Buffet A, Burnichon N, Favier J, Gimenez-Roqueplo A-P: An overview of
20 years of genetic studies in pheochromocytoma and paraganglioma.
Best Practice & Research Clinical Endocrinology & Metabolism.
2020:101416. 10.1016/j.beem.2020.101416
- Pacak K: New Biology of Pheochromocytoma and Paraganglioma. Endocrine
Practice. 2022:1253-1269. 10.1016/j.eprac.2022.09.003
- Al Subhi AR, Boyle V, Elston MS: Systematic Review: Incidence of
Pheochromocytoma and Paraganglioma Over 70 Years. Journal of the
Endocrine Society. 2022:105. 10.1210/jendso/bvac105
- Lenders JWM, Kerstens MN, Amar L, et al.: Genetics, diagnosis,
management and future directions of research of phaeochromocytoma and
paraganglioma: a position statement and consensus of the Working Group
on Endocrine Hypertension of the European Society of Hypertension.
Journal of Hypertension. 2020:1443-1456. 10.1097/HJH.0000000000002438
- Fagundes GFC, Almeida MQ: Perioperative Management of
Pheochromocytomas and Sympathetic Paragangliomas. Journal of the
Endocrine Society. 2022:004. 10.1210/jendso/bvac004
- Nazari MA, Hasan R, Haigney M, Maghsoudi A, Lenders JWM, Carey RM,
Pacak K: Catecholamine-induced hypertensive crises: current insights
and management. The. Lancet Diabetes & Endocrinology.
2023:942-954. 10.1016/S2213-8587(23)00256-5
- Aygun Nurcihan and Mehmet Uludag: Pheochromocytoma and paraganglioma:
from treatment to follow-up. Sisli Etfal. 2020,
54,4:391-398. 10.14744/SEMB.2020.58998
- Kim Y, Yoo YC, Kim NY, Shin HJ, Kweon KH, Moon J, Kang S-W: The
effects of perioperative dexmedetomidine infusion on hemodynamic
stability during laparoscopic adrenalectomy for pheochromocytoma: a
randomized study. Front Med. 2023:1276535. 10.3389/fmed.2023.1276535
- Bihain F, Nomine-Criqui C, Guerci P, Gasman S, Klein M, Brunaud
L: Management of Patients with Treatment of Pheochromocytoma: A
Critical Appraisal. Cancers. 2022:3845. 10.3390/cancers14163845
- Divya Mamilla, Katherine A. Araque, Alessandra Brofferio, Melissa
K: Gonzales, James N. Sullivan, Naris Nilubol, Karel Pacak.
Postoperative Management in Patients with Pheochromocytoma and
Paraganglioma. 2019:936. 10.3390/cancers11070936